title: Preparedness for infectious threats: public-private partnership to develop an affordable vaccine for an emergent threat: the trivalent Neisseria meningitidis ACW135 polysaccharide vaccine.
abstract: With the emergence of epidemic Neisseria meningitidis W135 meningitis in Burkina Faso during early 2002, the public health community was faced with the challenge of providing access to an appropriate and affordable vaccine in time for the upcoming 2003 epidemic season. Recognizing the implications of the emergent threat, the World Health Organization developed a strategy, established a public-private partnership to provide the needed vaccine, and then ensured that a stockpile was available for future use. The trivalent N meningitidis ACW135 polysaccharide vaccine that resulted is now one of the primary tools for epidemic response in African meningitis belt countries. It will remain so for the foreseeable future and until appropriate and affordable conjugate vaccines become part of national immunization programs in the region.
authors.affiliation: Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. christopher_nelson@merck.com
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Nelson
authors.forename: Maureen
authors.initials: M
authors.lastname: Birmingham
authors.forename: Alejandro
authors.initials: A
authors.lastname: Costa
authors.forename: Joelle
authors.initials: J
authors.lastname: Daviaud
authors.forename: William
authors.initials: W
authors.lastname: Perea
authors.forename: Marie-Paule
authors.initials: MP
authors.lastname: Kieny
authors.forename: Daniel
authors.initials: D
authors.lastname: Tarantola
mesh_terms: D002050:Burkina Faso / Q000453:epidemiology; D021821:Communicable Diseases, Emerging / Q000453:epidemiology / Q000517:prevention & control*; D004189:Disaster Planning / Q000458:organization & administration*; D004196:Disease Outbreaks; D006297:Health Services Accessibility; D006801:Humans; D017589:Immunization Programs; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology / Q000600:supply & distribution*; D038582:Neisseria meningitidis, Serogroup W-135 / Q000276:immunology / Q000302:isolation & purification*; D011159:Population Surveillance; D017149:Private Sector; D017150:Public Sector; D014944:World Health Organization
chemical_list: D022401:Meningococcal Vaccines